AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22338850 — intervention group
Group type: COMPARATOR
Intervention: Full-thickness flap technique (FT)
Number of subjects: 9
Study 15918162 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing
Number of subjects: 356
Study 15918162 — intervention group
Group type: COMPARATOR
Intervention: Not receiving academic detailing (Control)
Number of subjects: 356
Study 12390597 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 948
Study 12390597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 948
Study 9458325 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA (250 mg/m² on day 1) + FA (20 mg/m²) + 5-FU (400 mg/m², 5 min i.v. bolus injection) on days 2-5
Number of subjects: 6
Study 9458325 — intervention group
Group type: COMPARATOR
Intervention: 5-FU (400 mg/m², 5 min i.v. bolus injection) + FA (20 mg/m²) on days 2-5 without PALA
Number of subjects: 6
Study 7891486 — intervention group
Group type: EXPERIMENTAL
Intervention: Close supervision by nominated key-workers (intervention group)
Number of subjects: 400
Study 7891486 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up from psychiatric and social services (control group)
Number of subjects: 400
Study 2229705 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (education and psychological support in addition to routine care)
Number of subjects: 60
Study 2229705 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care only)
Number of subjects: 60
Study 365286 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed masturbation programme
Number of subjects: 35
Study 365286 — intervention group
Group type: COMPARATOR
Intervention: Combined sensate focus and supportive psychotherapeutic approach (Control)
Number of subjects: 35
Study 11774104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/d for 8 weeks
Number of subjects: 45
Study 11774104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 45
Study 11774104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31056482 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 91
Study 31056482 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 91
Study 30485325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue immunoglobulin G titres in children with prior medical diagnosis of dengue infection
Number of subjects: 865
Study 30485325 — intervention group
Group type: COMPARATOR
Intervention: Dengue immunoglobulin G titres in children without prior medical diagnosis of dengue infection
Number of subjects: 865
Study 30485325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue immunoglobulin G levels above the median value
Number of subjects: 865
Study 27919284 — intervention group
Group type: EXPERIMENTAL
Intervention: U-MDT
Number of subjects: 753
Study 27919284 — intervention group
Group type: COMPARATOR
Intervention: Regular MDT (R-MDT)
Number of subjects: 753
Study 27919284 — intervention group
Group type: EXPERIMENTAL
Intervention: ML Flow test positivity
Number of subjects: 753
Study 27919284 — intervention group
Group type: EXPERIMENTAL
Intervention: MB patients with high BI
Number of subjects: 753
Study 27919284 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative BI
Number of subjects: 753
Study 24747100 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy episodes for life-threatening VA
Number of subjects: 811
Study 24747100 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy episodes for life-threatening VA in patients not on beta-blocker therapy
Number of subjects: 811
Study 22689866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled lighting (CL)
Number of subjects: 37
Study 22689866 — intervention group
Group type: COMPARATOR
Intervention: Dim lighting (DL)
Number of subjects: 37
Study 20518617 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/indapamide fixed-dose combination
Number of subjects: 0
Study 20518617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose lowering with gliclazide modified release (MR)
Number of subjects: 0
Study 17651153 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE reactivity to Ara h2 before DBPCFC
Number of subjects: 20
Study 17651153 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE reactivity to Ara h6 before DBPCFC
Number of subjects: 20
Study 17651153 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE reactivity to Ara h1 and Ara h3 before DBPCFC
Number of subjects: 20
Study 17651153 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut-specific IgE levels before and after DBPCFC
Number of subjects: 20
Study 17651153 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with Ara h2 and Ara h6
Number of subjects: 20
Study 17651153 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with Ara h1 and Ara h3
Number of subjects: 20
Study 17651153 — intervention group
Group type: EXPERIMENTAL
Intervention: Weal size induced by Ara h6
Number of subjects: 20
Study 17651153 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship of parameters to severity of peanut allergy
Number of subjects: 20
Study 15985013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled IL-2 plus antiretroviral therapy (ART)
Number of subjects: 54
Study 15985013 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 54
Study 12921577 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus HIFU (T + H)
Number of subjects: 50
Study 12921577 — intervention group
Group type: COMPARATOR
Intervention: TACE (T)
Number of subjects: 50
Study 10646049 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril (1.5 mg/kg three times daily)
Number of subjects: 102
Study 10646049 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (0.03 mg/kg three times daily)
Number of subjects: 102
Study 10646049 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril
Number of subjects: 102
Study 10646049 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 102
Study 10646049 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril and Loperamide
Number of subjects: 102
Study 8660080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon alfa (3 million units/m2) for 12 months
Number of subjects: 21
Study 8660080 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 21
Study 1804731 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management programme (six 40-min sessions with a physiotherapist)
Number of subjects: 35
Study 1804731 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (including antispasmodic Colpermin)
Number of subjects: 35
Study 6683632 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin-cyclophosphamide (6 courses)
Number of subjects: 52
Study 6683632 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin-cyclophosphamide (6 courses) + Levamisole (immunotherapy for 2 years)
Number of subjects: 52
Study 30535333 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxidized oils (all oil sources)
Number of subjects: 200
Study 30535333 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxidized oils
Number of subjects: 200
Study 30535333 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxidized palm oil
Number of subjects: 200
Study 30535333 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxidized soybean oil
Number of subjects: 200
Study 30535333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil source (various oils)
Number of subjects: 200
Study 30390713 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruptive Behavior International Scale - Nepal version (DBIS-N)
Number of subjects: 268
Study 30390713 — intervention group
Group type: COMPARATOR
Intervention: Eyberg Child Behavior Inventory (ECBI)
Number of subjects: 268
Study 27456494 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics (oligofructose-enriched inulin 8 g orally/day)
Number of subjects: 0
Study 27456494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin 3.3 g orally/day)
Number of subjects: 0
Study 24818207 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved titanium abutment
Number of subjects: 26
Study 24818207 — intervention group
Group type: COMPARATOR
Intervention: Conventional titanium abutment (control)
Number of subjects: 26
Study 23119078 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 0
Study 23119078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20963579 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over left ventral premotor cortex (L-PMv)
Number of subjects: 0
Study 20963579 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 20963579 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over left dorsal premotor cortex (L-PMd)
Number of subjects: 0
Study 17331650 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogenic acellular dermal matrix (Group A)
Number of subjects: 72
Study 17331650 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine acellular dermal matrix (Group C)
Number of subjects: 72
Study 17331650 — intervention group
Group type: COMPARATOR
Intervention: Betadine ointment gauzes (Group B)
Number of subjects: 72
Study 17331650 — intervention group
Group type: COMPARATOR
Intervention: Betadine ointment gauzes (Group D)
Number of subjects: 72
Study 16279563 — intervention group
Group type: EXPERIMENTAL
Intervention: Food elimination diet based on skin prick and atopy patch testing results
Number of subjects: 146
Study 12350056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel
Number of subjects: 145
Study 12350056 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 145
Study 10195720 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 42
Study 10195720 — intervention group
Group type: COMPARATOR
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 42
Study 7786565 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanatory letter sent before telephone contact
Number of subjects: 2000
Study 7786565 — intervention group
Group type: COMPARATOR
Intervention: No explanatory letter sent before telephone contact
Number of subjects: 2000
Study 2195066 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational home visits by pharmacists
Number of subjects: 284
Study 2195066 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational home visits)
Number of subjects: 284
Study 475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 50 mg
Number of subjects: 12
Study 475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 100 mg
Number of subjects: 12
Study 475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg (base)
Number of subjects: 12
Study 475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine 10 mg
Number of subjects: 12
Study 475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine 5 mg
Number of subjects: 12
Study 475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 12
Study 475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 12
Study 475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Number of subjects: 12
Study 31403935 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity practice from childhood to adolescence
Number of subjects: 870
Study 31403935 — intervention group
Group type: COMPARATOR
Intervention: No physical activity practice from childhood to adolescence
Number of subjects: 870
Study 31094803 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg dexamethasone
Number of subjects: 60
Study 31094803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25955722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic cycling training (30 min, 55%-60% peak power, 3 days/week) for 3 months
Number of subjects: 18
Study 25955722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study 23097216 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 0.5% CLM (test; group 1)
Number of subjects: 98
Study 23097216 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo (control; group 2)
Number of subjects: 98
Study 22574814 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA® (n=20)
Number of subjects: 39
Study 22574814 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (n=19)
Number of subjects: 39
Study 22574814 — intervention group
Group type: COMPARATOR
Intervention: Comparison between EMLA® and placebo
Number of subjects: 39
Study 19713257 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (3 x 400 mg)
Number of subjects: 80
Study 19713257 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (3 x 100 mg)
Number of subjects: 80
Study 16876433 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motor learning
Number of subjects: 0
Study 16876433 — intervention group
Group type: COMPARATOR
Intervention: Explicit motor learning
Number of subjects: 0
Study 15553661 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 1967
Study 15553661 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 1967
Study 12394224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg B.I.D., clarithromycin (C) 500 mg B.I.D., metronidazole (M) 500 mg every morning and 1,000 mg every evening for 14 days
Number of subjects: 26
Study 12394224 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment with omeprazole (O) 20 mg, clarithromycin (C) 250 mg, metronidazole (M) 500 mg
Number of subjects: 26
Study 12394224 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment with ranitidine bismuth citrate (RBC) 400 mg, tetracycline (T) 1,000 mg, metronidazole (M) 500 mg
Number of subjects: 26
Study 9917784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival mitomycin C (0.25 ml of 0.2 mg/ml)
Number of subjects: 9
Study 9917784 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 9
Study 9917784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival mitomycin C
Number of subjects: 9
Study 8772214 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose oral anticoagulants (OAC) - acenocoumarol, target INR 2.0-3.0
Number of subjects: 672
Study 8772214 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose subcutaneous low molecular weight heparin (LMWH) - nadroparine, 60 aXa IU/kg once daily
Number of subjects: 672
Study 8772214 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose oral anticoagulants (OAC)
Number of subjects: 672
Study 8772214 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose subcutaneous low molecular weight heparin (LMWH) - nadroparine
Number of subjects: 672
Study 2206004 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0
Study 2206004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7302997 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with Krestin
Number of subjects: 0
Study 7302997 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 31267794 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic Health Warnings (GHWs)
Number of subjects: 244
Study 31267794 — intervention group
Group type: COMPARATOR
Intervention: Text-only cigarette pack
Number of subjects: 244
Study 27405902 — intervention group
Group type: EXPERIMENTAL
Intervention: All-around nursing care
Number of subjects: 98
Study 27405902 — intervention group
Group type: COMPARATOR
Intervention: General nursing care
Number of subjects: 98
Study 28880416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot application
Number of subjects: 96
Study 28880416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application
Number of subjects: 96
Study 28880416 — intervention group
Group type: COMPARATOR
Intervention: Standard osteoarthritis treatment (Control)
Number of subjects: 96
Study 27690505 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily (25 mg) plus targeted (25 mg) naltrexone
Number of subjects: 127
Study 27690505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 24419808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 41
Study 24419808 — intervention group
Group type: COMPARATOR
Intervention: Control group (metallic stent)
Number of subjects: 41
Study 22959714 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EESs)
Number of subjects: 2774
Study 22959714 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 2774
Study 19734765 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial optic neurotomy (RON)
Number of subjects: 22
Study 19734765 — intervention group
Group type: COMPARATOR
Intervention: Cannulation of tissue plasminogen activator (tPA)
Number of subjects: 22
Study 17522511 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal management protocol (intravenous fluid restriction, unrestricted oral intake with prokinetic agents, early ambulation, fixed regimen epidural analgesia)
Number of subjects: 70
Study 17522511 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous fluids to prevent oliguria, restricted oral intake until return of bowel motility, weaning regimen epidural analgesia)
Number of subjects: 70
Study 15199352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment for hyperlipidemia
Number of subjects: 4451
Study 15199352 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining an ideal weight
Number of subjects: 4451
Study 15199352 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 4451
Study 15199352 — intervention group
Group type: COMPARATOR
Intervention: Weight > or = 25 kg/m2
Number of subjects: 4451
Study 15199352 — intervention group
Group type: COMPARATOR
Intervention: Weight gain
Number of subjects: 4451
Study 15199352 — intervention group
Group type: COMPARATOR
Intervention: Becoming inactive
Number of subjects: 4451
Study 15199352 — intervention group
Group type: COMPARATOR
Intervention: Older age
Number of subjects: 4451
Study 15199352 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 4451
Study 15199352 — intervention group
Group type: COMPARATOR
Intervention: Treatment for hyperlipidemia
Number of subjects: 4451
Study 11578723 — intervention group
Group type: COMPARATOR
Intervention: Lim-XRT (Pelvic irradiation): 50 Gy in 25 fractions over 5 weeks
Number of subjects: 484
Study 11578723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ext-XRT (Extended irradiation): 50 Gy in pelvis + 25 Gy to para-aortic nodes and liver in 19 fractions over 25 days
Number of subjects: 484
Study 11225452 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 15
Study 11225452 — intervention group
Group type: COMPARATOR
Intervention: Conventional cholecystectomy
Number of subjects: 15
Study 11225452 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life scores
Number of subjects: 15
Study 9143575 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy
Number of subjects: 75
Study 9143575 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy with gastric substitute
Number of subjects: 75
Study 9143575 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy
Number of subjects: 75
Study 9143575 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study 7955286 — intervention group
Group type: COMPARATOR
Intervention: Right atrial approach (group B)
Number of subjects: 107
Study 7955286 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular approach (group A)
Number of subjects: 107
Study 3579683 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional speech therapy provided by professional speech pathologists twice weekly
Number of subjects: 60
Study 3579683 — intervention group
Group type: COMPARATOR
Intervention: Emotionally supportive counseling therapy provided by professional speech pathologists at the same intervals
Number of subjects: 60
Study 1760712 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded mixture
Number of subjects: 142
Study 1760712 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique with separate bottles
Number of subjects: 142
Study 786317 — intervention group
Group type: EXPERIMENTAL
Intervention: mineralocorticoid
Number of subjects: 13
Study 786317 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 786317 — intervention group
Group type: EXPERIMENTAL
Intervention: sympathomimetic drug
Number of subjects: 13
Study 31820339 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05280586
Number of subjects: 394
Study 31820339 — intervention group
Group type: COMPARATOR
Intervention: Rituximab-EU
Number of subjects: 394
Study 30527440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%
Number of subjects: 181
Study 30527440 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 0.5%
Number of subjects: 181
Study 28668914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1-0.7 μg/kg per hour, titrated by patient-triggered doses of 0.25 μg/kg)
Number of subjects: 37
Study 28668914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 37
Study 28668914 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 37
Study 27684818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT with iterative model reconstruction (IMR)
Number of subjects: 60
Study 27684818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT with hybrid iterative reconstruction (HIR)
Number of subjects: 60
Study 27684818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT with filtered back projection (FBP)
Number of subjects: 60
Study 27684818 — intervention group
Group type: COMPARATOR
Intervention: Routine-dose CT with filtered back projection (FBP)
Number of subjects: 60